News
Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback